Share
14,237 Posts.
lightbulb Created with Sketch. 4256
clock Created with Sketch. 12/02/25
13:39
Share
Originally posted by AlCp:
↑
The IP need to advance to show they are working in order to attract partnership or sold. There has only been one clinical trial update for VAXINIA and Azer-Cel 14 and 5 months ago, that's why the next 2-5 (VAXINIA and OASIS) and then 8-11 months (Azer-Cel) are very important to IMU with more data release for these IP. Like I've already told you, there was some concern around toxicity for Azer-Cel and more data are required to see if the combination with IL-2 has addressed this so why will there be interest right now??? The next development stage for Azer-Cel is to obtain Fast Track designation with these data provided they continue to be excellent and then gain registrational clinical trial.
Expand
We can discuss it to oblivion, in the end the market will have the final say.
(20min delay)